MedTrace Logo

Statins In The Elderly

NCT02547883 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1230

Last updated 2023-02-24

No results posted yet for this study

Summary

In patients ≥ 75 years, there is no evidence that statins in primary prevention are associated with a decreased mortality and recent US recommendations consider statins in people only between 40 and 75 years. Moreover, statins are associated with numerous side effects impacting quality of life of those people and represent a high cost for the French healthcare system.

The aim of the present study is to evaluate cost/effectiveness ratio, in real life, of statin cessation in people ≥ 75 years treated in primary prevention.

Conditions

  • Mortality

Interventions

DRUG

Cessation of statin

The intervention evaluated is the cessation of statin

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Antoine BENARD · USMR - CHU de Bordeaux

  • Jean-philippe JOSEPH, Pr · University of Bordeaux

  • Fabrice BONNET, Pr · University Hospital, Bordeaux

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-15
Primary Completion
2023-01-31
Completion
2023-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02547883 on ClinicalTrials.gov